Emmi Puujalka

Emmi Puujalka

Auto-generated profile, based on publicly available information

Emmi Puujalka

Skin and Endothelium Research Division, Department of Dermatology, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
MHMagdalena Heinz
Magdalena Heinz
HNHeide Leb Niederleithner
Heide Leb Niederleithner
EPEmmi Puujalka
Emmi Puujalka
ASAna Soler-Cardona
Ana Soler-Cardona
Michael GruschMichael Grusch
Michael Grusch
PPPeter Petzelbauer
Peter Petzelbauer

1 April 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
JWJudith Wenzina
Judith Wenzina
SHSilvio Holzner
Silvio Holzner
EPEmmi Puujalka
Emmi Puujalka
PCPhil Cheng
Phil Cheng
AFAgnes Forsthuber
Agnes Forsthuber
PPPeter Petzelbauer
Peter Petzelbauer
Melanoma cells can switch between distinct gene expression profiles, resulting in proliferative or invasive phenotypes. Signaling pathways involved in this switch were analyzed by gene expression profiling of a cohort of 22 patient-derived melanoma cell lines. CDH1 negativity was identified as a surrogate marker for the invasive phenotype. CDH1 expression could be turned on and off by modulating activity of p38 or its downstream target MK2, suggesting that this pathway controls melanoma progression. Mechanistically, MK2 inhibition prevented melanoma-induced vascular barrier disruption, reduced the expression of PODXL and DEL-1, and prevented vascular dissemination in vivo. PODXL and DEL-1 expression in patients with melanoma were associated with poor survival and thus can be used as prognostic markers. Downstream targets of MK2 may thus serve as candidate therapeutics.

1 May 2016 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
EPEmmi Puujalka
Emmi Puujalka
MHMagdalena Heinz
Magdalena Heinz
BHBastian Hoesel
Bastian Hoesel
PFPeter Friedl
Peter Friedl
BSBernhard Schweighofer
Bernhard Schweighofer
PPPeter Petzelbauer
Peter Petzelbauer
In primary melanoma, the amount of vascular endothelial growth factor C (VEGF-C) expression and lymphangiogenesis predicts the probability of metastasis to sentinel nodes, but conditions boosting VEGF-C expression in melanoma are poorly characterized. By comparative mRNA expression analysis of a set of 22 human melanoma cell lines, we found a striking negative correlation between VEGF-C and microphthalmia-associated transcription factor (MITF) expression, which was confirmed by data mining in GEO databases of human melanoma Affymetrix arrays. Moreover, in human patients, high VEGF-C and low MITF levels in primary melanoma significantly correlated with the chance of metastasis. Pathway analysis disclosed the respective c-Jun N-terminal kinase and p38/mitogen-activated protein kinase activities as being responsible for the inverse regulation of VEGF-C and MITF. Predominant c-Jun N-terminal kinase signaling results in a VEGF-C(low)/MITF(high) phenotype; these melanoma cells are highly proliferative, show low mobility, and are poorly lymphangiogenic. Predominant p38 signaling results in a VEGF-C(high)/MITF(low) phenotype, corresponding to a slowly cycling, highly mobile, lymphangiogenic, and metastatic melanoma. In conclusion, the relative c-Jun N-terminal kinase and p38 activities determine the biological behavior of melanoma. VEGF-C and MITF levels serve as surrogate markers for the respective c-Jun N-terminal kinase and p38 activities and may be used to predict the risk of metastasis in primary melanoma.